分组1 - Viridian Therapeutics reported a quarterly loss of $1.08 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.90, and compared to a loss of $0.81 per share a year ago, indicating an earnings surprise of -20.67% [1] - The company posted revenues of $0.13 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 99.29%, and this was an increase from revenues of $0.07 million a year ago [2] - The stock has underperformed the market, losing about 7% since the beginning of the year, while the S&P 500 gained 1.5% [3] 分组2 - The earnings outlook for Viridian Therapeutics is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Viridian Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.98 on $0.1 million in revenues, and for the current fiscal year, it is -$3.50 on $88.07 million in revenues [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Viridian Therapeutics belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook for stocks in this sector [8]

分组1 - Codexis reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.15, and an improvement from a loss of $0.29 per share a year ago, indicating an earnings surprise of -46.67% [1] - The company posted revenues of $8.6 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 53.96%, and down from $12.83 million in the same quarter last year [2] - Codexis shares have declined approximately 54.9% year-to-date, contrasting with the S&P 500's gain of 15.6% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $23.61 million, and for the current fiscal year, it is -$0.67 on revenues of $65.14 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 41% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]